Last ¥4,547 JPY
Change Today +1.00 / 0.02%
Volume 1.2M
4502 On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Frankfurt
As of 2:00 AM 04/18/14 All times are local (Market data is delayed by at least 15 minutes).

takeda pharmaceutical co ltd (4502) Snapshot

Open
¥4,542
Previous Close
¥4,546
Day High
¥4,560
Day Low
¥4,525
52 Week High
04/25/13 - ¥5,520
52 Week Low
06/13/13 - ¥4,180
Market Cap
3.6T
Average Volume 10 Days
4.6M
EPS TTM
¥130.89
Shares Outstanding
789.7M
EX-Date
03/27/14
P/E TM
34.7x
Dividend
¥180.00
Dividend Yield
3.96%
Current Stock Chart for TAKEDA PHARMACEUTICAL CO LTD (4502)

Related News

No related news articles were found.

takeda pharmaceutical co ltd (4502) Related Businessweek News

View More BusinessWeek News

takeda pharmaceutical co ltd (4502) Details

Takeda Pharmaceutical Company Limited is engaged in supplying pharmaceutical products worldwide. The company provides products in various therapeutic areas, including cardiovascular and metabolic, oncology, central nervous system, respiratory and immunology, and gastrointestinal and genitourinary, as well as vaccines. It is also involved in the manufacture and sale of OTC drugs and quasi-drugs, reagents, clinical diagnostics, and chemical products. Takeda Pharmaceutical Company Limited was founded in 1781 and is based in Osaka, Japan.

30,481 Employees
Last Reported Date: 06/26/13
Founded in 1781

takeda pharmaceutical co ltd (4502) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

takeda pharmaceutical co ltd (4502) Key Developments

Takeda Pharmaceutical Company Limited Announces Availability of ADCETRI 50mg for Intravenous Drip Infusion in Japan

Takeda Pharmaceutical Company Limited announced that 'ADCETRIS® 50mg for intravenous drip infusion' (brentuximab vedotin) is now available for the treatment for patients with CD30 Positive Relapsed or Refractory Hodgkin Lymphoma (HL) or Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL) in Japan. ADCETRIS received orphan drug designation from the Ministry of Health, Labour and Welfare (MHLW) in March 2012, and Japanese manufacturing and marketing authorization on January 17th 2014. Additionally, ADCETRIS was placed on the country's National Health Insurance drug price list today, April 17th 2014. ADCETRIS is an antibody-drug conjugate (ADC) comprised of an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics' proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

Japanese Ministry of Health, Labour and Welfare Approves Takeda Pharmaceutical's NDA for Cell Cultured Influenza Vaccine

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Takeda Pharmaceutical's new drug application (NDA) of Cell Cultured Influenza vaccine H5N1 'TAKEDA' 1mL (Cell Cultured Influenza vaccine (H5N1Strain)) and Cell Cultured Influenza vaccine (Prototype) 'TAKEDA' 1mL (Cell Cultured Influenza vaccine (Prototype)) for prevention of pandemic influenza. The new vaccine will be manufactured at a newly-established facility at the company's Hikari Plant in Hikari City, Yamaguchi Prefecture. The company has submitted the NDA to MHLW in March 2013 and the approval means that Takeda is now able to manufacture and supply pandemic influenza vaccines in Japan using new manufacturing technologies licensed from Baxter.

Trianni, Inc., and Takeda Pharmaceutical Company Limited Enter into a License Agreement

Trianni, Inc., and Takeda Pharmaceutical Company Limited, have entered into a license agreement for Takeda's use of the Trianni Mouse, a monoclonal antibody discovery platform. Trianni Mouse will provide Takeda with an access to a complete human antibody repertoire that has been optimized for the isolation of fully human therapeutics.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4502:JP ¥4,547.00 JPY +1.00

4502 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $197.39 USD -1.99
Astellas Pharma Inc ¥1,139 JPY -1.00
Baxter International Inc $72.81 USD -0.64
Becton Dickinson and Co $113.16 USD +0.23
Merck KGaA €115.25 EUR +0.45
View Industry Companies
 

Industry Analysis

4502

Industry Average

Valuation 4502 Industry Range
Price/Earnings 35.8x
Price/Sales 2.2x
Price/Book 1.5x
Price/Cash Flow 35.7x
TEV/Sales 1.3x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAKEDA PHARMACEUTICAL CO LTD, please visit www.takeda.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.